Ascendis Pharma 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Ascendis Pharma reported Q3 2026 product revenue of €366 million, up 89% year over year and €51 million sequentially, reflecting demand across its 3 marketed products.
- Uropat revenue was €291 million, up 103% year over year and €39 million sequentially; Urovel revenue was €16 million, doubling from €8 million in Q2; and Skytrofa revenue was €59 million, up €4 million sequentially.
- Operating expenses were €217 million, down €32 million from Q2; reported operating profit was €125 million, and non-IFRS operating profit was €156 million, a 42% margin.
- Cash flow from operating activities was €189 million in Q3, and cash at quarter-end was €964 million, up €152 million from Q2.
- From September 30th through November 11th, 2026, Ascendis spent $273 million US dollars repurchasing 1.2 million ordinary shares; year-to-date, it had repurchased 2 million shares for approximately $460 million US dollars.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Ladies and gentlemen, thank you for standing by. Welcome to the third quarter 2026 Ascendis Pharma earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you would need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would like now to turn the conference over to Chad Fugere, Vice President and Investor Relations.
Please go ahead. Thank you, operator, and thank you, everyone, for joining our third quarter 2026 financial results conference call.
I am Chad Fugere, Vice President, Investor Relations at Ascendis Pharma. Joining me on the call today are Jan Mikkelsen, President and Chief Executive Officer, Scott Smith, Chief Financial Officer, and Jay Wu, Executive Vice President and President, U.S. Market. Before we begin, I would like to remind everyone that certain matters discussed on today's conference call are forward-looking statements relating to future events, future financial performance, and management's plans and objectives for the business. These statements are subject to risks and uncertainties, and actual results could differ materially from those anticipated in the forward-looking statements.
The risk factors may affect results are described in our annual report on Form 20-F, filed with the SEC on February 11, 2026, as such report may be updated by other public filings with the SEC from time to time. The forward-looking statements made today are as of the date of this call, and we do not undertake any obligation to update these forward-looking statements. The speakers on today's call may also refer to certain non-IFRS financial measures. A reconciliation of these non-IFRS financial measures to the most directly comparable IFRS measures is available in our press release issued today. Content of this call is not intended to constitute and should not be interpreted as direct or indirect promotion of any of our products or product candidates. A copy of this press release may be obtained by visiting the investor relations page of our website at investors.ascendispharma.com.
With that, I will turn the call over to Jan.
Thanks, Chad. Good day, everyone. In the third quarter, execution across R&D and commercial continued to drive the transformation of Ascendis Pharma into a leading global biopharma company, strengthening our ability to make a meaningful difference for patients. In Q3, we delivered product revenue of EUR 366 million, up 89% over last year, and up EUR 51 million over last quarter, reflecting strong new patient demand across all three of our market products. Looking ahead, we see three complementary drivers of durable growth. First, continued growth for our existing three products in already approved indication. Second, expansion of indication for our three existing products, including label extension for monotherapy and combination therapy. Third, new products enabled by our TransCon technology platform to drive sustainable long-term growth.
Importantly, our global geographic commercial expansion will further accelerate growth of all three drivers over the coming years, as more and more countries will be fully commercial. Our R&D and commercial infrastructure give us confidence that we can achieve our Vision 2030 goals of generating over EUR 5 billion in annual product revenue in 2030, and develop new multiple blockbuster products with the TransCon technology platform, which also including a new therapeutic era. Let us start with the first driver, continued growth for our existing three products, YORVIPATH, YUVIWEL, and SKYTROFA, in already approved indication. YORVIPATH is the first and only approved treatment for hypoparathyroidism in adults, and is now available commercially or through name patient programs in more than 40 countries. Global YORVIPATH revenue in the third quarter was EUR 291 million, up 103% over last year, and up EUR 39 million over last quarter.
In the U.S., new patient demand in the third quarter was consistent with prior quarters, even during the summer months. With an estimated 70,000 to 90,000 adults that live with chronic hypoparathyroidism in the U.S., and more than 90% of the estimated number of patients are still potential candidates for YORVIPATH PTH replacement therapy. In September, we launched a U.S. national disease awareness campaign designed to help patients identify symptoms and empower them to speak with their healthcare provider about treatment options. We expect the campaign's impact to build gradually over the coming quarters and are planning to launch additional awareness campaigns in 2027. Outside the U.S., revenue continues to grow quarter by quarter, with full commercial availability for YORVIPATH in 13 countries and 15 additional markets expected in 2027.
YORVIPATH's robust uptake is supported by clinical data that showed its ability to maintain normal serum calcium and phosphate, and normalized urinary calcium and phosphate excretion, and normalized active vitamin D production, achieve independence from conventional therapy, and improve quality of life, skeletal health, and kidney function. To our knowledge, no therapy in development has shown this depth and breadth of benefit across multiple target organ systems. As the only approved PTH replacement therapy, we believe YORVIPATH has set a high bar and is positioned to be the standard of care in hypoparathyroidism treatment for many, many years to come. Looking ahead, we expect sustainable growth in patients on YORVIPATH in both established and new markets, as our clinical studies demonstrate that nearly all patients with hypoparathyroidism benefit from treatment. Turning now to YUVIWEL. YUVIWEL is the first and only approved therapy for children with achondroplasia to offer continuous systemic exposure to active CNP with a once-weekly dosing.
In the third quarter, YUVIWEL revenue was EUR 16 million. New patient demand in the U.S. has been steady through Q3. We have now around 340 patients enrolled through October, with more than 80% of these already approved for reimbursement. We see patients switching from daily therapy, returning to medical therapy, and starting treatment for the first time. YUVIWEL is growing the U.S. market and is on track to unlock its potential to become the market-leading therapy for children with achondroplasia. Through October, the number of new YUVIWEL enrollment equals nearly half of all U.S. patients on pharmacological treatment before our April launch.
With around 70% of children with achondroplasia in the U.S. still untreated, we see a substantial opportunity ahead to address the significant unmet needs and health complications associated with achondroplasia. In addition to showing statistically significant linear growth improvement, such as height and body proportionality, YUVIWEL is, to our knowledge, the only therapy approved in development to have demonstrated significant improvements in key measures of skeletal proportionality, lower limb alignment, spinal canal dimension compared to placebo. It has also shown improvement in health-related quality of life and physical function, with a safety and tolerability profile compared to placebo, all elements critical for chronic therapy in children. Outside the U.S., we received a positive CHMP opinion in October and a positive COMP opinion to maintain orphan medicinal product designation, which, if approved, provides the potential for up to 10 years of market exclusivity.
We now expect a European Commission decision on our MAA before year-end. If approved, we plan our first European launch in Germany in Q1 2027. We are also making YUVIWEL available in select international markets through early access programs and expect to recognize revenue from multiple countries outside of the U.S. and E.U. in the coming quarters. Turning now to SKYTROFA, the only once-weekly growth hormone treatment to provide unmodified somatropin. SKYTROFA remains the number one long-acting growth hormone by value in the U.S. Third-quarter revenue was EUR 59 million, driven by higher patient demand. Now to our second driver of growth, expansion of indication across our three marketed products, which are supported by more than 20 ongoing or planned studies. For YORVIPATH, this include a U.S. trial to increase dosing up to 60 micrograms, as well as ongoing multinational trials in patients aged 12 to 17.
We also continue to progress a once-weekly PTH program designed for patients who have attained stable doses of daily YORVIPATH. For YUVIWEL, we are working to expand into additional achondroplasia age group and hypochondroplasia. Our ongoing infant trial is fully enrolled, with top-line results expected in 2027. This past quarter, we presented early sentinel data for this trial that showed once-weekly TransCon CNP providing stabilization or improvement in foramen magnum stenosis, as well as linear growth benefit. In addition, TransCon CNP was generally well tolerated, with no reported of injection site reaction over 52 weeks. Lastly, we plan to initiate a phase II proof-of-concept trial in adults with achondroplasia before year-end, where we believe TransCon CNP might offer benefit in physical function, mobility, chronic pain, fatigue, and/or other areas that affect daily living. We also expect to initiate a phase III trial in children with hypochondroplasia this quarter.
For SKYTROFA, which is being studied in more indications than any other long-acting growth hormone, our basket trial in patients with ISS, SGA, SHOX deficiency, and Turner syndrome is progressing. With growth hormone deficiency representing only about 50% of the available growth hormone market, approval across these indications could double the patient population addressed by our current label. We anticipate complete enrollment in this trial in the first half of 2027. Combination therapy with TransCon CNP and TransCon growth hormone is another important program. Market research suggests this unique combination could become the future standard of care in achondroplasia.
Our phase II COACH trial showed that TransCon growth hormone added to therapy with TransCon CNP led to significant improved efficacy versus TransCon CNP monotherapy, with up to three to four-fold greater improvement in ACH-specific height Z-score, as well as improvement in arm span body proportionality, sustained through 78 weeks, without any compromise to safety or tolerability. Patient recruitment for our phase III combination trial in children with achondroplasia has started, while a separate phase III combination trial in children with hypochondroplasia is planned to be initiated in 2027. We continue to expand our global commercial presence across all three products, working toward full commercialization of our products in more than 50 countries. Turning now to the third driver, new products. As I mentioned upfront, the TransCon technology platform enables the creation of highly differentiated new products, which we believe will be a major driver of sustainability for Ascendis.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
16 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
